Zhang L J, Lachowicz J E, Sibley D R
Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892.
Mol Pharmacol. 1994 May;45(5):878-89.
To investigate and compare the regulatory properties of the two isoforms of the D2 dopamine receptor, we have stably expressed their cDNAs in Chinese hamster ovary (CHO) cells. Cell lines were selected that express similar levels of [3H]methylspiperone-binding activity. Both isoforms mediate a dose-dependent and pharmacologically specific inhibition of adenylyl cyclase activity in both intact cell and membrane preparations. Pretreatment of both D2L and D2S receptor-expressing cells with 100 microM dopamine produces a approximately 5-fold shift (to lower affinity) in the EC50 for dopamine inhibition of cAMP accumulation, with a 25-30% decrease in the maximum response. Dopamine treatment also results in a approximately 25% decrease in the maximum receptor binding activity of the D2S receptor-expressing cells. In contrast, the D2L receptors are up-regulated by about 2-fold in response to dopamine exposure. This difference in response between the D2S and D2L receptors is not cell line specific, inasmuch as other CHO clones expressing these isoforms show identical responses. The dopamine-induced up-regulation of D2L receptor binding is time dependent, reaching maximal levels after 10 hr (t1/2 = 2 hr). Upon removal of dopamine, the receptor binding activity returns to control levels within 20 hr. The adenylyl cyclase desensitization response is also time dependent but exhibits a slower time course (t1/2 = 5 hr) than the receptor up-regulation. Both regulatory responses are induced in a dose-dependent fashion by dopamine, albeit with different potencies (up-regulation EC50 = 100 nM, desensitization EC50 = 2 microM). These regulatory effects are pharmacologically specific, being mimicked by D2-selective agonists but not agonists of other receptor subtypes. The dopamine-induced receptor up-regulation is blocked by prior treatment of the cells with pertussis toxin and is not mimicked by cAMP analogs. Conversely, elevation of intracellular cAMP levels results in down-regulation of the D2L receptor activity. To test whether protein synthesis is required for the D2L receptor up-regulation, cycloheximide was used to block mRNA translation. This was found to completely inhibit the up-regulation of D2L binding activity; however, there was no effect on the desensitization of the adenylyl cyclase response. RNA dot-blot analyses indicate that dopamine treatment is associated with a sustained 2-fold increase in the steady state levels of D2L mRNA, whereas D2S mRNA is transiently increased by only 50%.(ABSTRACT TRUNCATED AT 400 WORDS)
为了研究和比较D2多巴胺受体两种亚型的调节特性,我们已将其cDNA稳定转染至中国仓鼠卵巢(CHO)细胞中。筛选出表达相似水平的[3H]甲基螺哌隆结合活性的细胞系。两种亚型在完整细胞和细胞膜制剂中均介导对腺苷酸环化酶活性的剂量依赖性和药理学特异性抑制。用100μM多巴胺预处理表达D2L和D2S受体的细胞,会使多巴胺抑制cAMP积累的EC50产生约5倍的偏移(亲和力降低),最大反应降低25 - 30%。多巴胺处理还导致表达D2S受体的细胞的最大受体结合活性降低约25%。相反,D2L受体在多巴胺暴露后上调约2倍。D2S和D2L受体之间的这种反应差异并非细胞系特异性的,因为表达这些亚型的其他CHO克隆显示出相同的反应。多巴胺诱导的D2L受体结合上调是时间依赖性的,10小时后达到最大水平(t1/2 = 2小时)。去除多巴胺后,受体结合活性在20小时内恢复到对照水平。腺苷酸环化酶脱敏反应也是时间依赖性的,但比受体上调表现出更慢的时间进程(t1/2 = 5小时)。两种调节反应均由多巴胺以剂量依赖性方式诱导,尽管效力不同(上调EC50 = 100 nM,脱敏EC50 = 2μM)。这些调节作用在药理学上是特异性的,可被D2选择性激动剂模拟,但不能被其他受体亚型的激动剂模拟。多巴胺诱导的受体上调被百日咳毒素预先处理细胞所阻断,且不能被cAMP类似物模拟。相反,细胞内cAMP水平升高导致D2L受体活性下调。为了测试D2L受体上调是否需要蛋白质合成,使用放线菌酮阻断mRNA翻译。发现这完全抑制了D2L结合活性的上调;然而,对腺苷酸环化酶反应的脱敏没有影响。RNA斑点印迹分析表明,多巴胺处理与D2L mRNA稳态水平持续增加2倍相关,而D2S mRNA仅短暂增加50%。(摘要截断于400字)